The veterans affairs high-density lipoprotein intervention trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol-Reference-Cited by-同舟云学术

The veterans affairs high-density lipoprotein intervention trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol

Published:1996-09 Issue:5 Volume:78 Page:572-575
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Rubins Hanna Bloomfield,Robins Sander J.,Collins Dorothea

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference17 articles.

1. Distribution of lipids in 8,500 men with coronary artery disease;Rubins;Am J Cardiol,1995

2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

3. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens;Am J Cardiol,1995

4. Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol

5. The effects of fibrates on lipoprotein and hemostatic coronary risk factors;Schonfeld;Atherosclerosis,1994

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease;International Journal of Molecular Sciences;2023-01-25

2. Fibrate pharmacogenomics: expanding past the genome;Pharmacogenomics;2020-03

3. Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs;International Journal of Molecular Sciences;2019-10-31

4. A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors†;Journal of Pharmacy and Pharmacology;2019-07-29

5. Cardiovascular Health and Healthy Aging;Healthy Aging;2019